1. P674 Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohort. (30th January 2023) Authors: Verstockt ., B; Vieujean, S; Truyens, M; Julsgaard, M; Pugliese, D; Aslan, D; Prokopic, M; Lim, S; Viganò, C; Festa, S; Ramos, L; Garciá, M J; Plaza, R; Noviello, D; Savarino, E; Drobne, D; Imperatore, N; Ribaldone, D G; Van Dongen, J; Teich, N Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i805 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P782 Ustekinumab in Ulcerative colitis: a real-life effectiveness study across multiple Belgian centers (SULTAN). (30th January 2023) Authors: Holvoet, T; Truyens, M; Reenaers, C; Baert, F; Vandenbranden, S; Cremer, A; Pouillon, L; Dewint, P; Van Moerkercke, W; Rahier, J F; Vandermeulen, L; Van Dongen, J; Peeters, H; Lambrecht, G; Vijverman, A; Lobaton, T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i916 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗